NeoGenomics shares rise 2.50% premarket after FDA approval of breakthrough cancer therapies.

NeoGenomics, Inc. rose 2.50% in premarket trading, driven by the FDA's approval of breakthrough therapies for aggressive malignancies, including Modeyso for deadly brain tumors. This regulatory momentum is generating substantial opportunities for companies with cutting-edge oncology platforms, such as NeoGenomics, Inc.